
TScan Therapeutics (TCRX) Stock Forecast & Price Target
TScan Therapeutics (TCRX) Analyst Ratings
Bulls say
TScan Therapeutics Inc. demonstrates a significant potential for growth due to its promising clinical results in liquid tumor therapies, particularly with its TSC-100 and TSC-101 candidates showing a notable 70% improvement in event-free survival (EFS) and a remarkably low relapse rate of 8% compared to 33% in the control arm. The company's strategic development of multiplex TCR-T therapies for solid tumors is supported by the recent FDA clearance for an additional immunotherapy candidate, facilitating broader treatment options for patients, especially in non-small cell lung cancer. TScan is expected to capitalize on its innovative approach and strong early efficacy data, positioning itself for pivotal studies aimed at expanding its market presence in both hematologic malignancies and solid tumor sectors.
Bears say
TScan Therapeutics Inc reported a significantly increased net loss of $35.8 million, or ($0.30 per share), in the fourth quarter of 2024, compared to a loss of $19.6 million, or ($0.21 per share), in the same quarter of the previous year. There are concerns that the company's upcoming clinical updates may reveal multiple patient relapses in its TSC-100 and TSC-101 therapies, leading to a reduction in its probability of success in treating hematological malignancies to 45%. Additional worries persist regarding TScan's potential inability to develop further successful clinical candidates beyond its current programs, contributing to a negative outlook on the company's stock valuation and performance.
This aggregate rating is based on analysts' research of TScan Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
TScan Therapeutics (TCRX) Analyst Forecast & Price Prediction
Start investing in TScan Therapeutics (TCRX)
Order type
Buy in
Order amount
Est. shares
0 shares